Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

BACKGROUND: E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of either E39 or E39′ (an attenuated version of E39) to prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Tommy A., Byrd, Kevin, Vreeland, Timothy J., Clifton, Guy T., Jackson, Doreen O., Hale, Diane F., Herbert, Garth S., Myers, John W., Greene, Julia M., Berry, John S., Martin, Jonathan, Elkas, John C., Conrads, Thomas P., Darcy, Kathleen M., Hamilton, Chad A., Maxwel, George L., Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712444/
https://www.ncbi.nlm.nih.gov/pubmed/31274231
http://dx.doi.org/10.1002/cam4.2378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712444/
https://www.ncbi.nlm.nih.gov/pubmed/31274231
http://dx.doi.org/10.1002/cam4.2378

Ejemplares similares